Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tsumura & Co ( (JP:4540) ) has shared an announcement.
Tsumura & Co. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2026, due to recent performance trends and strategic acquisitions. The company expects a 5.3% increase in net sales, primarily driven by the consolidation of Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd. Although operating profit is projected to rise by 49.8%, the impact of the acquisition is expected to be minor due to associated costs. The company has also increased its annual dividend forecast by 8 yen per share, reflecting improved profitability and a commitment to shareholder returns.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen3870.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
More about Tsumura & Co
Tsumura & Co. operates in the pharmaceutical industry, focusing on the production and distribution of traditional Chinese medicine products. The company is listed on the TSE Prime Market and has a significant market presence in both domestic and Chinese markets.
YTD Price Performance: -22.02%
Average Trading Volume: 390,846
Technical Sentiment Signal: Hold
Current Market Cap: Yen271.5B
For a thorough assessment of 4540 stock, go to TipRanks’ Stock Analysis page.